Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Glutamine supplement tested for IBS relief in new study

NCT ID NCT06291038

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking glutamine, a natural amino acid, can reduce symptoms in people with diarrhea-predominant irritable bowel syndrome (IBS-D) who also have increased intestinal permeability (leaky gut). About 60 adults will receive either glutamine or a placebo daily for 8 weeks. The goal is to see if glutamine improves IBS severity scores and gut barrier function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult aged 18 to 75 * Diarrheal irritable bowel syndrome (IBS-D), according to the Rome IV criteria (appendix 2) * Francis score \> 175/500 at inclusion (corresponding to moderate to severe IBS) * Treatments for IBS stable for \>1 month * Affiliation to a social security system * Adult person having read and understood the information letter and signed the consent form * Woman of childbearing age having effective/very effective contraception (Cf. CTFG) (estrogen-progestins or intrauterine device or tubal ligation) for 1 month and a negative urine pregnancy test * Postmenopausal woman: confirmatory diagnosis (amenorrhea not medically induced for at least 12 months before the inclusion visit or biologically documented) Exclusion Criteria: * Taking probiotics, anti-inflammatories, corticosteroids or antibiotics systemically (oral or injectable) in the month preceding the study and during the duration of the study treatment, * Known diagnosis of active autoimmune disease (type 1 diabetes, lupus, multiple sclerosis, thyroiditis, ankylosing spondylitis, rheumatoid arthritis or psoriasis) * Known allergy to glutamine, * Contraindication to taking glutamine, protein powder, lactulose or mannitol (including sugar-free chewing gum), * Use of osmotic laxatives and/or taking lactulose and/or protein supplementation (including taking glutamine) in the 4 weeks preceding the start of the study, * Renal insufficiency (GFR\<40mL/min), hepatic insufficiency (PT\<70) or known heart disease, * ATCD of digestive disease (celiac disease, chronic inflammatory bowel disease, abdominal surgery other than appendectomy or cholecystectomy), * Occlusive or subocclusive syndrome, * Digestive perforation or suspicion of perforation, * Abdominal pain syndrome of undetermined cause, * Chronic alcohol consumption (\>14 units/week), * Pregnant or parturient or breastfeeding woman or proven absence of contraception, * Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection/under guardianship or curatorship, * Person participating in research participating in another trial / having participated in another trial within 2 weeks, * History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or preventing them from giving informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Irritable bowel syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU CAEN

    RECRUITING

    Caen, 14033, France

  • Ch Le Havre

    RECRUITING

    Le Havre, 76290, France

  • Chu Amiens

    NOT_YET_RECRUITING

    Amiens, 80054, France

  • Chu Rouen

    RECRUITING

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.